四月 11, 2014

【實證醫學】克流感(Tamiflu)效果不佳,副作用明顯(2014)&瑞樂沙(Relenza)效果不佳,副作用也不明顯(2014)

【實證醫學】克流感(Tamiflu)效果不佳,副作用明顯(2014)
 
Oseltamivir (Tamiflu) for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348: g2545.
Conclusions: In prophylactic studies oseltamivi⋯⋯r reduces the proportion of symptomatic influenza. In treatment studies it also modestly reduces the time to first alleviation of symptoms, but it causes nausea and vomiting and increases the risk of headaches and renal and psychiatric syndromes. The evidence of clinically significant effects on complications and viral transmission is limited because of rarity of such events and problems with study design. The trade-off between benefits and harms should be borne in mind when making decisions to use oseltamivir for treatment, prophylaxis, or stockpiling.
http://www.bmj.com/content/348/bmj.g2545.pdf%2Bhtml
【實證醫學】瑞樂沙(Relenza)效果不佳,副作用也不明顯(2014)
 
Zanamivir (Relenza) for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348: g2547.
Conclusions: Based on a full assessment of all trials conducted, zanamivir reduces the time to symptomatic improvement in adults (but not in children) with influenza-like illness by just over half a day, alt⋯⋯hough this effect might be attenuated by symptom relief medication. Zanamivir also reduces the proportion of patients with laboratory confirmed symptomatic influenza. We found no evidence that zanamivir reduces the risk of complications of influenza, particularly pneumonia, or the risk of hospital admission or death. Its harmful effects were minor (except for bronchospasm), perhaps because of low bioavailability.
http://www.bmj.com/content/348/bmj.g2547.pdf%2Bhtml
星星原文PDF參考星星
Oseltamivir for influenza in adults and children.pdf
Zanamivir for influenza in adults and children- systematic review of clinical study reports and summary of regulatory comments.pdf


發佈者: 療癒系健康中心 at 10:51│  點閱次數 (680)│ 修改文章管理迴響置頂公告

回應文章

 
 

Powered by LifeType. Design by colaccl.com

Bad Behavior 已經阻擋了 22 個過去 7 天試圖闖關的垃圾迴響與引用。